Introduction. Frailty syndrome is characterized by increased vulnerability of elderly and senile individuals to external factors, as well as impairment of physical, functional, and/or cognitive status. The "Age is not a hindrance" questionnaire is widely used in our country. In patients with type 2 diabetes, frailty is three to five times more common than in individuals without impaired carbohydrate metabolism. There is substantial evidence that type 2 diabetes contributes to the development and severity of frailty. Loss of muscle mass and deterioration of muscle function are described by many authors as complications of type 2 diabetes. Aim: to determine the specific features of the geriatric status and the measure to achieve the goals of clinical and metabolic control of elderly patients with type 2 diabetes (DM2). Material and methods: the study was performed using a single-stage slice design; the data of a comprehensive geriatric examination and laboratory and instrumental indicators of therapeutic control of diabetes in a sample of 155 comorbid elderly patients with DM2 were studied; the frequency of detection of key geriatric syndromes (frailty and sarcopenia according to the EWGSOP2 protocol) and achievement of targets for glycemic, lipidemic and hemodynamic control of diabetes were determined. Results: in the sample of elderly patients with DM2, there was a high prevalence of frailty in men and women (28.6% and 53.5%), pre-frailty (46.4% and 33.1%); as well as pronounced sarcopenia (21.4% and 51.2%), confirmed sarcopenia (17.9% and 3.1%); significant differences were identified the social status of participants based on gender; a high frequency of failure to achieve the goals of therapeutic control of diabetes, in particular, indicators of lipid metabolism and hemodynamics, was revealed. Conclusions: the prevalence of frailty and sarcopenia in elderly patients with DM2 exceeds general population indicators; significant differences in social status parameters in men and women can have a significant impact on the personalization of therapeutic management of diabetes in old age; the imbalance between achieving the target values of glycemic and lipidemic control of diabetes has a significant impact on cardiovascular risk and treatment effectiveness.